In May 2019, we reviewed the evidence for prostate cancer in the following areas:

- Diagnosing and identifying clinically significant prostate cancer
- Following up people at increased risk of prostate cancer
- Active surveillance, radical prostatectomy or radical radiotherapy in people with localised prostate cancer
- Identifying prostate cancer clinical progression in people with low- to intermediate-risk cancer
- Radical radiotherapy
- Docetaxel in people with hormone-sensitive prostate cancer
- Follow-up protocols after radical treatment
- Bisphosphonates

See the guideline scope for more information about why we decided to update this guideline.